Fig. 7: Glioma growth is inhibited by administration of MNPs-loaded CELSR2-siRNA.
From: Atypical cadherin CELSR2 acts as a therapeutic target for glioma through WNT3A/β-catenin signaling
A Schematic diagram of MNPs-loaded CELSR2-siRNA. B PB stain revealed MNPs-loaded CELSR2-siRNA were ingested by cultured U87 MG cells. (C) CELSR2 mRNA levels were significantly decreased in the siRNA group and siRNA MNPs group compared to the control group. D, E EDU labeling showed a significant decrease in proliferating cells in the siRNA group and siRNA MNPs group. F, G Flow cytometry showed altered cell-cycle distribution (S phase decrease and G0/G1 increase in the siRNA group and siRNA MNPs group compared to the control). H Schematic diagram of nude mice inoculated with U87 MG cells and administration. I, J The tumor volume and average weight were significantly smaller in the siRNA MNPs group than in the control and MNPs groups. K, L The results of dynamic measurements of tumor volume and mouse body weight in live animals. M, N EDU labelling revealed a significant decrease in proliferating cells in the siRNA MNPs group compared to the control and MNPs groups. Scale bar is 100 μm in (D) and 50 μm in (M). Data are represented as mean ± SEM. Two-way repeated measures ANOVA with Bonferroni’s post hoc correction in (K, L) and one-way ANOVA analysis of variance with Tukey’s multiple comparison in others. *P < 0.05, **P < 0.01, n = 3 in (B–G) and n = 8 in (H–N). (A) and (H) created with BioRender.
